Monopar Therapeutics (MNPR) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for June 17, 2025, with record date of April 25, 2025; 6,115,214 shares outstanding, each with one vote.

• Four proposals up for vote: election of six directors, advisory vote on executive compensation, advisory vote on frequency of say-on-pay, and ratification of BPM LLP as auditor.

• Board unanimously recommends voting for all proposals and for annual say-on-pay votes.

• Proxy materials and annual report available online; shareholders encouraged to vote by proxy or in person.

Voting matters and shareholder proposals

• Proposal 1: Elect six current directors to serve until the next annual meeting.

• Proposal 2: Advisory, non-binding vote on executive compensation (first year for say-on-pay proposal).

• Proposal 3: Advisory, non-binding vote on frequency of say-on-pay (Board recommends every year).

• Proposal 4: Ratification of BPM LLP as independent auditor for 2025.

• No other business or director nominees expected; procedures for shareholder proposals for 2026 outlined.

Board of directors and corporate governance

• Board consists of six members, including CEO and Executive Chairman; four are independent per Nasdaq standards.

• Board committees: Audit, Compensation, Corporate Governance & Nominating, and Plan Administrator.

• All directors attended at least 75% of meetings in 2024; five of six attended last annual meeting.

• Board leadership separates CEO and Executive Chairman roles for effective oversight.

• Board and committees conduct annual self-evaluations and charter reviews.